VolitionRX Ltd: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über VolitionRX Ltd Unternehmen

VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

VolitionRX Ltd Informationen



BörsenkürzelVNRX

Name des UnternehmensVolitionRX Ltd

IPO-datumFeb 06, 2015

CEOButera (Salvatore Thomas)

Anzahl der mitarbeiter85

WertpapierartOrdinary Share

GeschäftsjahresendeFeb 06

Addresse1489 West Warm Springs Road

StadtHENDERSON

BörseNASDAQ OMX – NASDAQ Basic Amex

LandUnited States of America

Postleitzahl89014

Telefon17024251561

Websitehttps://volition.com/

BörsenkürzelVNRX

IPO-datumFeb 06, 2015

CEOButera (Salvatore Thomas)

Führungskräfte von VolitionRX Ltd



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Guy Archibald Innes

Independent Director

2.99M

+12000.00%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.38M

+74700.00%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

480.16K

+35400.00%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

437.35K

+49200.00%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

378.80K

+53400.00%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

245.61K

+42000.00%

Dr. Alan Colman, Ph.D.

Independent Director

215.55K

+12000.00%

Mr. Gael Forterre

Chief Commercial Officer

189.87K

-2010.00%

Mr. Nicholas Plummer

Group General Counsel

189.64K

-5647.00%

Mr. Rodney Gerard Rootsaert

Corporate Secretary

162.26K

-3196.00%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Guy Archibald Innes

Independent Director

2.99M

+12000.00%

Mr. Cameron John Reynolds

President, Chief Executive Officer, Director

2.38M

+74700.00%

Dr. Jacob Vincent Micallef

Chief Scientific Officer

480.16K

+35400.00%

Mr. Terig Hughes

Chief Financial Officer, Treasurer

437.35K

+49200.00%

Dr. Salvatore Thomas Butera

Chief Executive Officer of Volition Vet

378.80K

+53400.00%

Dr. Jasmine Kway

Chief Executive Officer of Singapore Volition

245.61K

+42000.00%

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Thu, Feb 5

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Lagoda Investment Management, L.P.

10.17%

Cotterford Co., Ltd.

9.78%

Armistice Capital LLC

7.64%

Innes (Guy Archibald)

2.44%

Reynolds (Cameron John)

1.94%

Andere

68.04%

Aktionäre

Anteil

Lagoda Investment Management, L.P.

10.17%

Cotterford Co., Ltd.

9.78%

Armistice Capital LLC

7.64%

Innes (Guy Archibald)

2.44%

Reynolds (Cameron John)

1.94%

Andere

68.04%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

12.09%

Corporation

10.60%

Hedge Fund

8.00%

Individual Investor

7.00%

Investment Advisor/Hedge Fund

1.12%

Research Firm

0.04%

Venture Capital

0.03%

Andere

61.13%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

58

26.12M

21.27%

+1.98M

2025Q3

57

23.92M

20.70%

+1.72M

2025Q2

78

41.39M

40.30%

+860.69K

2025Q1

83

44.42M

46.85%

+2.70M

2024Q4

82

41.53M

44.82%

+1.50M

2024Q3

82

38.59M

41.90%

+9.42M

2024Q2

82

28.77M

32.86%

+105.49K

2024Q1

84

28.22M

34.52%

+1.47M

2023Q4

87

26.17M

37.10%

+183.39K

2023Q3

91

25.37M

36.48%

-477.38K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Lagoda Investment Management, L.P.

12.49M

10.17%

+782.00K

+6.68%

Sep 30, 2025

Cotterford Co., Ltd.

12.01M

9.78%

--

Apr 25, 2025

Armistice Capital LLC

9.38M

7.64%

+887.35K

+10.45%

Sep 30, 2025

Innes (Guy Archibald)

2.98M

2.43%

+96.15K

+3.33%

Oct 14, 2025

Reynolds (Cameron John)

2.31M

1.88%

+20.00K

+0.87%

Nov 17, 2025

The Vanguard Group, Inc.

1.53M

1.25%

-94.68K

-5.83%

Sep 30, 2025

Concord International Inc.

1.01M

0.82%

--

Apr 25, 2025

Geode Capital Management, L.L.C.

878.17K

0.72%

+113.28K

+14.81%

Sep 30, 2025

Micallef (Jacob Vincent)

444.76K

0.36%

-5.85K

-1.30%

Oct 04, 2025

BlackRock Institutional Trust Company, N.A.

445.19K

0.36%

--

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0%

iShares Micro-Cap ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten